TrialInternational journal of hematology2009

A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.

Yukari Shirasugi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.